These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 20429826)

  • 21. Aqueous solubility: simple predictive methods (in silico, in vitro and bio-relevant approaches).
    Elder D; Holm R
    Int J Pharm; 2013 Aug; 453(1):3-11. PubMed ID: 23124107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High throughput solubility measurement in drug discovery and development.
    Alsenz J; Kansy M
    Adv Drug Deliv Rev; 2007 Jul; 59(7):546-67. PubMed ID: 17604872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparative assessment of solubility advantage from glassy and crystalline forms of a water-insoluble drug.
    Chawla G; Bansal AK
    Eur J Pharm Sci; 2007 Sep; 32(1):45-57. PubMed ID: 17618092
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Solubility of crystalline organic compounds in high and low molecular weight amorphous matrices above and below the glass transition by zero enthalpy extrapolation.
    Amharar Y; Curtin V; Gallagher KH; Healy AM
    Int J Pharm; 2014 Sep; 472(1-2):241-7. PubMed ID: 24968139
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapid conversion of API hydrates to anhydrous forms in aqueous media.
    Petrova RI; Peresypkin A; Mortko CJ; McKeown AE; Lee J; Williams JM
    J Pharm Sci; 2009 Nov; 98(11):4111-8. PubMed ID: 19384923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What is the true solubility advantage for amorphous pharmaceuticals?
    Hancock BC; Parks M
    Pharm Res; 2000 Apr; 17(4):397-404. PubMed ID: 10870982
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the crystalline and amorphous states of drug products by nanothermal analysis and Raman imaging.
    Nakamoto K; Urasaki T; Hondo S; Murahashi N; Yonemochi E; Terada K
    J Pharm Biomed Anal; 2013 Mar; 75():105-11. PubMed ID: 23246930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids.
    Morissette SL; Almarsson O; Peterson ML; Remenar JF; Read MJ; Lemmo AV; Ellis S; Cima MJ; Gardner CR
    Adv Drug Deliv Rev; 2004 Feb; 56(3):275-300. PubMed ID: 14962582
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Calculation of aqueous solubility of crystalline un-ionized organic chemicals and drugs based on structural similarity and physicochemical descriptors.
    Raevsky OA; Grigor'ev VY; Polianczyk DE; Raevskaja OE; Dearden JC
    J Chem Inf Model; 2014 Feb; 54(2):683-91. PubMed ID: 24456022
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Strategies at the interface of drug discovery and development: early optimization of the solid state phase and preclinical toxicology formulation for potential drug candidates.
    Palucki M; Higgins JD; Kwong E; Templeton AC
    J Med Chem; 2010 Aug; 53(16):5897-905. PubMed ID: 20527889
    [No Abstract]   [Full Text] [Related]  

  • 31. Solubility advantage from amorphous etoricoxib solid dispersions.
    Dani P; Puri V; Bansal AK
    Drug Dev Ind Pharm; 2014 Jan; 40(1):92-101. PubMed ID: 23301771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of Accuracy of Amorphous Solubility Advantage Calculation by Comparison with Experimental Solubility Measurement in Buffer and Biorelevant Media.
    Zhang W; Haser A; Hou HH; Nagapudi K
    Mol Pharm; 2018 Apr; 15(4):1714-1723. PubMed ID: 29522344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Solubility advantage of amorphous pharmaceuticals, part 3: Is maximum solubility advantage experimentally attainable and sustainable?
    Murdande SB; Pikal MJ; Shanker RM; Bogner RH
    J Pharm Sci; 2011 Oct; 100(10):4349-56. PubMed ID: 21630280
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An example of how to handle amorphous fractions in API during early pharmaceutical development: SAR114137--a successful approach.
    Petzoldt C; Bley O; Byard SJ; Andert D; Baumgartner B; Nagel N; Tappertzhofen C; Feth MP
    Eur J Pharm Biopharm; 2014 Apr; 86(3):337-50. PubMed ID: 24075979
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An Examination of Water Vapor Sorption by Multicomponent Crystalline and Amorphous Solids and Its Effects on Their Solid-State Properties.
    Newman A; Zografi G
    J Pharm Sci; 2019 Mar; 108(3):1061-1080. PubMed ID: 30391302
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of enthalpy and Gibbs free energy to evaluate the risk of amorphous formation.
    Hsieh DS; Sarsfield BA; Davidovich M; DiMemmo LM; Chang SY; Kiang S
    J Pharm Sci; 2010 Sep; 99(9):4096-105. PubMed ID: 20564337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Progress in the research of amorphous pharmaceuticals].
    Ying J; Lü Y; Du GH
    Yao Xue Xue Bao; 2009 May; 44(5):443-8. PubMed ID: 19618716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nuances in the Calculation of Amorphous Solubility Enhancement Ratio.
    Manchanda A; Kleppe MS; Bogner RH
    J Pharm Sci; 2019 Nov; 108(11):3560-3574. PubMed ID: 31271772
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In silico prediction of the solubility advantage for amorphous drugs - Are there property-based rules for drug discovery and early pharmaceutical development?
    Kuentz M; Imanidis G
    Eur J Pharm Sci; 2013 Feb; 48(3):554-62. PubMed ID: 23262058
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The solid-state continuum: a perspective on the interrelationships between different solid-state forms in drug substance and drug product.
    Elder DP; Patterson JE; Holm R
    J Pharm Pharmacol; 2015 Jun; 67(6):757-72. PubMed ID: 25124049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.